Literature DB >> 11836668

Multimodality treatment of diffuse malignant pleural mesothelioma.

Lambros S Zellos1, David J Sugarbaker.   

Abstract

Diffuse malignant pleural mesothelioma (DMPM) is a challenging disease in all of its aspects, from presentation and diagnosis to staging and treatment. Single-modality therapy was the initial approach to this disease. It generally has not been effective in changing the natural history of DMPM. As a result, multimodality regimens involving surgery with radiation, chemotherapy, or immunotherapy delivered regionally or systemically have been evaluated. Randomized controlled studies comparing various strategies are lacking and, thus, the debate continues regarding the effectiveness of different treatment approaches. Copyright 2002 by W.B. Saunders Company.

Entities:  

Mesh:

Year:  2002        PMID: 11836668     DOI: 10.1053/sonc.2002.30230

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.

Authors:  Suresh S Ramalingam; Chandra P Belani; Christopher Ruel; Paul Frankel; Barbara Gitlitz; Marianna Koczywas; Igor Espinoza-Delgado; David Gandara
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

2.  Generation and characterization of an ascitogenic mesothelin-expressing tumor model.

Authors:  Wen-Fang Cheng; Chien-Fu Hung; Chee-Yin Chai; Chi-An Chen; Chien-Nan Lee; Yi-Ning Su; Wen-Yih Isaac Tseng; Chang-Yao Hsieh; Ie-Ming Shih; Tian-Li Wang; T-C Wu
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

3.  Control of human mesothelin-expressing tumors by DNA vaccines.

Authors:  C-L Chang; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2007-06-21       Impact factor: 5.250

Review 4.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

Review 5.  Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.

Authors:  Anders Hjerpe; Valeria Ascoli; Carlos Bedrossian; Mathilde Boon; Jenette Creaney; Ben Davidson; Annika Dejmek; Katalin Dobra; Ambrogio Fassina; Andrew Field; Pinar Firat; Toshiaki Kamei; Tadao Kobayashi; Claire W Michael; Sevgen Önder; Amanda Segal; Philippe Vielh
Journal:  Cytojournal       Date:  2015-11-30       Impact factor: 2.091

6.  Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.

Authors:  Hesham A El Hossieny; Fatma Aboulkasem; M Abdel Rahman
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-01

7.  Solitary Fibrous Tumor of the Pleura: A Rare Cause of Pleural Mass.

Authors:  Rodjawan Supakul; Amik Sodhi; Cecilia Yshii Tamashiro; Syed S Azmi; Dipen Kadaria
Journal:  Am J Case Rep       Date:  2015-12-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.